HLH Management: A Multidisciplinary Approach
HLH requires management by multiple subspecialties working collaboratively, with hematology/oncology typically serving as the primary coordinating specialty for most cases, though rheumatology leads when HLH presents as macrophage activation syndrome (MAS) in the context of autoimmune disease. 1
Primary Managing Specialties
The 2019 Histiocyte Society guidelines explicitly identify that HLH challenges subspecialists across multiple domains including 1:
- Hematology/oncology (primary for most HLH cases)
- Rheumatology/clinical immunology (primary for MAS-HLH)
- Infectious diseases
- Gastroenterology/hepatology
- Neurology
- Emergency medicine
- Intensive care medicine
- General medicine
Specialty-Specific Consultation Patterns
For Infection-Triggered HLH (e.g., EBV-HLH)
Hematology/oncology is the preferred first consultant for most providers, though notably only 47% of rheumatologists agree with this approach 2. This reflects the need for chemotherapy-based protocols (dexamethasone and etoposide) that hematology/oncology specialists are most comfortable administering.
For MAS-HLH (Autoimmune-Triggered)
92% of respondents across all specialties favor rheumatology consultation first 2. This makes sense given that MAS-HLH treatment differs from other HLH forms, often requiring immunosuppressive agents like anakinra and cyclosporine rather than chemotherapy-based regimens 1.
For Critically Ill Patients
Intensive care specialists play a crucial role in managing the multisystem organ failure that characterizes severe HLH, requiring early aggressive critical care interventions 3. Critical care teams must work alongside the primary managing specialty.
Why Multiple Specialties Are Essential
The multidisciplinary requirement stems from HLH's complex pathophysiology:
- Different triggers require different expertise: Infections need infectious disease input, malignancies require oncology expertise, and autoimmune conditions need rheumatology 1
- Rapid progression to multiorgan failure necessitates intensive care involvement 3
- Diagnostic complexity requires coordinated testing across specialties 2
Current Practice Gaps
A major problem exists: 50% of providers are unaware of institutional algorithms for HLH diagnosis and treatment 2. This highlights why 85.6% of clinicians favor developing standardized treatment algorithms, and 90% support formal multidisciplinary HLH teams 2.
Practical Recommendation
Establish institutional multidisciplinary HLH teams with hematology/oncology and rheumatology as co-leads, supported by infectious disease, critical care, and other relevant specialties. The specific lead specialty should be determined by the underlying trigger: hematology/oncology for infection- or malignancy-associated HLH, and rheumatology for MAS-HLH 1, 2.
Critical Caveat
Early recognition prevents irreversible organ damage and death 1. Any delay in specialty consultation while determining the "correct" specialty can be fatal. When in doubt, consult both hematology/oncology and rheumatology simultaneously, as current consulting patterns show significant variation by specialty that may delay appropriate care 2.